<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002973</url>
  </required_header>
  <id_info>
    <org_study_id>TP-19902</org_study_id>
    <nct_id>NCT04002973</nct_id>
  </id_info>
  <brief_title>Desaturation Validation of INVSENSOR00037</brief_title>
  <official_title>Desaturation Validation of INVSENSOR00037</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masimo Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masimo Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the trending accuracy of a noninvasive regional oximetry&#xD;
      measurement of somatic oxygen saturation. One investigational sensor (INVSENSOR00037) will be&#xD;
      placed on the somatic site of the volunteer. The values obtained by the test sensor will be&#xD;
      compared to the reference value obtained from an FDA-cleared sensor placed on the somatic&#xD;
      site on the contralateral side.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2019</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trending Accuracy of the INVSENSOR00037</measure>
    <time_frame>1-5 hours</time_frame>
    <description>This study will evaluate the trending accuracy of the INVSENSOR00037 relative to the reference value obtained from the comparative FDA-cleared device.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>INVSENSOR00037</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00037.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>INVSENSOR00037</intervention_name>
    <description>Noninvasive regional oximeter.</description>
    <arm_group_label>INVSENSOR00037</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is between 18 and 50 years of age.&#xD;
&#xD;
          -  Subject weighs a minimum of 110 lbs and no more than 250 lbs unless subject is over 6&#xD;
             feet tall.&#xD;
&#xD;
          -  Must have a hemoglobin value greater than or equal to 11 g/dL.&#xD;
&#xD;
          -  Baseline heart rate ≥ 45 bpm and ≤ 85 bpm.&#xD;
&#xD;
          -  Blood Pressure (Systolic BP &lt; 140 mmHg and Diastolic BP &lt; 90 mmHg).&#xD;
&#xD;
          -  Carbon monoxide (CO) value less than or equal to 2.0% fractional carboxyhemoglobin&#xD;
             (FCOHb)&#xD;
&#xD;
          -  Subject has a physical status of ASA I or II (American Society of Anesthesiology Class&#xD;
             I; Healthy subjects without any systemic disease at all. American Society of&#xD;
             Anesthesiology Class II; subjects with mild systemic disease) as it applies to the&#xD;
             systemic disease portion of the classification.&#xD;
&#xD;
          -  Subject is able to read and communicate in English and understands the study and risks&#xD;
             involved.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant. Subject smokes (including e-cigarette use).&#xD;
&#xD;
          -  Subject has a BMI &gt; 35 and has been classified as morbidly obese or at an increased&#xD;
             risk for participation by a medical professional.&#xD;
&#xD;
          -  Subject has a history of fainting (vasovagal), blacking out or losing consciousness&#xD;
             during or after a blood draw, or has a fear of blood draws.&#xD;
&#xD;
          -  Subject has open wounds, inflamed tattoos or piercings and/or visible healing wounds&#xD;
             that a medical professional renders them at an increased risk for participation.*&#xD;
&#xD;
          -  Subject experiences frequent or severe headaches and/or migraine headaches, migraine&#xD;
             auras, altitude sickness, and/or headaches accompanied by visual changes or&#xD;
             sensitivity to light or sound.&#xD;
&#xD;
          -  Subject has known drug or alcohol abuse and/or uses recreational drugs.&#xD;
&#xD;
          -  Subject has experienced a concussion or head injury with loss of consciousness within&#xD;
             the last year.&#xD;
&#xD;
          -  Subject has any chronic bleeding disorders (i.e. hemophilia).&#xD;
&#xD;
          -  Subject has any history of a stroke, myocardial infarction, seizures or heart attack.&#xD;
&#xD;
          -  Subject has any cancer or history of cancer (not including skin cancer)*.&#xD;
&#xD;
          -  Subject has a known neurological and/or psychiatric disorder (i.e. schizophrenia,&#xD;
             bipolar disorder, Multiple Sclerosis, Huntington's disease) that interferes with the&#xD;
             subjects' level of consciousness.&#xD;
&#xD;
          -  Subject has any cardiac dysrhythmia(s) (i.e. atrial fibrillation) and has not received&#xD;
             clearance by their physician to participate.&#xD;
&#xD;
          -  Subject has Wolff-Parkinson-White Syndrome or Stokes-Adams Syndrome.&#xD;
&#xD;
          -  Subject has taken anticoagulant medication within the last 30 days (excluding&#xD;
             nonsteroidal anti-inflammatory drugs (NSAIDS)).&#xD;
&#xD;
          -  Subject has donated blood within the past 4 weeks.&#xD;
&#xD;
          -  Subject has taken opioid pain medication within 24 hours before the study.&#xD;
&#xD;
          -  Subject has any type of infectious disease (i.e. Hepatitis, HIV, Tuberculosis, Flu,&#xD;
             Malaria, Measles, etc.).&#xD;
&#xD;
          -  Subject is taking medications known to treat any type of infectious disease.&#xD;
&#xD;
          -  Subject has either signs or history of peripheral ischemia or carpal tunnel syndrome.&#xD;
&#xD;
          -  Subject has had invasive surgery within the past year- including but not limited to&#xD;
             major dental surgery*, appendix*, plastic surgery*.&#xD;
&#xD;
          -  Subject has had invasive surgery within the past year- including but not limited&#xD;
             gallbladder, major fracture repairs (involving plates/ screws), jaw surgery, urinary&#xD;
             tract surgery, major ENT surgery, joint replacement or gynecological surgeries, heart&#xD;
             surgery or thoracic surgery.&#xD;
&#xD;
          -  Subject has symptoms of congestion, head colds, flu or other illnesses.&#xD;
&#xD;
          -  Subject is claustrophobic and/or has generalized anxiety disorder.&#xD;
&#xD;
          -  Subject has been in severe car accident(s) or a similar type of accident(s) requiring&#xD;
             hospitalization within the last 12 months.&#xD;
&#xD;
          -  Subject has chronic unresolved asthma, lung disease or respiratory disease.&#xD;
&#xD;
          -  Subject is allergic to lidocaine, latex, adhesives, or plastic.&#xD;
&#xD;
          -  Subject has a heart condition, insulin-dependent diabetes or uncontrolled&#xD;
             hypertension.&#xD;
&#xD;
          -  Subject has delivered vaginally, has had a pregnancy terminated, a miscarriage with&#xD;
             hospitalization or had a C-section within the last 6 months.&#xD;
&#xD;
          -  Subject has any medical condition which in the judgment of the investigator and/or&#xD;
             medical staff, renders them ineligible for participation in this study (Discretion of&#xD;
             investigator/study staff).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Masimo Corporation</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <results_first_submitted>September 25, 2020</results_first_submitted>
  <results_first_submitted_qc>September 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2020</results_first_posted>
  <disposition_first_submitted>June 26, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>June 26, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 3, 2020</disposition_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT04002973/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>INVSENSOR00037</title>
          <description>All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00037.&#xD;
INVSENSOR00037: Noninvasive regional oximeter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>INVSENSOR00037</title>
          <description>All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00037.&#xD;
INVSENSOR00037: Noninvasive regional oximeter.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trending Accuracy of the INVSENSOR00037</title>
        <description>This study will evaluate the trending accuracy of the INVSENSOR00037 relative to the reference value obtained from the comparative FDA-cleared device.</description>
        <time_frame>1-5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>INVSENSOR00037</title>
            <description>All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00037.&#xD;
INVSENSOR00037: Noninvasive regional oximeter.</description>
          </group>
        </group_list>
        <measure>
          <title>Trending Accuracy of the INVSENSOR00037</title>
          <description>This study will evaluate the trending accuracy of the INVSENSOR00037 relative to the reference value obtained from the comparative FDA-cleared device.</description>
          <units>percentage of regional oxygen saturation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 to 5 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>INVSENSOR00037</title>
          <description>All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00037.&#xD;
INVSENSOR00037: Noninvasive regional oximeter.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chelsea Frank</name_or_title>
      <organization>Masimo</organization>
      <phone>(949) 297-7000</phone>
      <email>studies@masimo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

